Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD5 CAR-T cells |
Synonyms | |
Therapy Description |
CD5 CAR-T cells are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting CD5 fused to the intracellular signaling domain of CD28 and the T-cell receptor (TCR) zeta chain, which potentially induce toxicity against CD5-expressing tumor cells and inhibit tumor growth (PMID: 26056165). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD5 CAR-T cells | autologous CD5.CAR/28zeta CAR T cells|Anti-CD5 CAR T cells | CD5 CAR-T cells are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting CD5 fused to the intracellular signaling domain of CD28 and the T-cell receptor (TCR) zeta chain, which potentially induce toxicity against CD5-expressing tumor cells and inhibit tumor growth (PMID: 26056165). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |